ASCO 2022: The latest in RCC

Bookmark and Share
Published: 17 Jun 2022
Views: 1109
Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri

Prof James Larkin (The Royal Marsden Hospital, London, UK), Dr Bernard Escudier (Institut Gustave Roussy, Villejuif, France), Prof Jens Bedke (Tübingen University Hospital, Tübingen, Germany) and Dr Toni Choueiri (Dana-Farber Cancer Institute, Boston, USA) discuss the latest in mRCC and RCC from ASCO 2022.

The panel consider the latest treatment options for RCC, and new data announced at ASCO 2022. They touch on the CheckMate 214, KEYNOTE-564, EVEREST, KEYNOTE-427 and CLEAR studies which look at a range of therapies including immunotherapy and tyrosine kinase inhibitors.

They discuss the variety of endpoints used for trials in renal cancer, what they mean for patients, and consider the adjuvant setting.

They also discuss quality of life (QoL) data from the meeting and how it is increasingly becoming important in the modern treatment landscape.

ecancer's filming has been kindly supported by Eisai through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.